Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 225-897-8 | CAS number: 5137-70-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Remarks:
- other: screening OECD 421 study
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- from 2012-03-02 to 2012-10-17
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- GLP study (OECD 421). The results of mortality/clinical signs, food consumption, body weight, gross pathology and histopathology were used to support the results observed in the key study.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 012
- Report date:
- 2012
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: OECD 421
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- 2011-07-19
- Limit test:
- no
Test material
- Reference substance name:
- Octylphosphonic acid
- EC Number:
- 225-218-5
- EC Name:
- Octylphosphonic acid
- Cas Number:
- 4724-48-5
- Molecular formula:
- C8H19O3P
- IUPAC Name:
- octylphosphonic acid
- Test material form:
- other: cream waxy granular solid
- Details on test material:
- - Name of test material (as cited in study report): octylphosphonic acid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: River Laboratories France, L’Arbresle, France
- Age at study initiation: 11 weeks old
- Weight at study initiation: Males: 419 g (range 389 g to 447 g) ; Females: 218 g (range: 195 g to 242 g)
- Housing: The animals were individually housed, except during pairing and lactation, in polycarbonate cages (Tecniplast 2154, 940 cm²) with stainless steel lids, and containing autoclaved sawdust (SICSA, Alfortville, France).Toward the end of gestation and during lactation with their litter, autoclaved wood shavings (SICSA Alfortville, France) was provided as nesting material, a few days before delivery and during the lactation period. Each cage contained an object for the environmental enrichment of the animals. The cages were placed in numerical order on the racks.
- Diet: free access to SSNIFF R/M-H pelleted maintenance diet, batch No. 55776558 (SSNIFF Spezialdiäten GmbH, Soest, Germany) which was distributed weekly
- Water (e.g. ad libitum): free access to bottles containing tap water (filtered with a 0.22 µm filter)
- Acclimation period: 5 days before the beginning of the treatment period
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2°C
- Humidity (%): 50 ± 20%,
- Air changes (per hr): about 12 cycles/hour of filtered, non-recycled air
- Photoperiod (hrs dark / hrs light): 12h/12h
IN-LIFE DATES: From: 2012-03-22 To: 2012-05-05
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test item was administered as a suspension in the vehicle. The test item was ground to a fine powder, using a mortar and pestle, and then mixed with the required quantity of vehicle. No correction factor was applied. The dose-levels of the test item were expressed in terms of the test item as supplied.
The dose formulations were prepared for up to 11 days (frequency based on the results of the stability study CIT/Study No. 38540 AHS).
The dose formulations were stored at room temperature, protected from light, and delivered to the study room in brown flasks.
VEHICLE
- Justification for use and choice of vehicle (if other than water): No data
- Concentration in vehicle:12, 30 and 80 mg/kg
- Amount of vehicle (if gavage): 5 mL /kg
- Lot/batch no. (if required): MKBG9425V and MKBF8603V
- Purity: No data - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The concentration of the test item in samples of each control and test item dose formulation prepared for use in weeks 1, 3 and 6 was determined. These analyses were performed prior to administration of the dose formulations to the animals.
Acceptance criterion: measured concentration = nominal concentration ± 15%
The test item concentrations in the administered dose formulations analyzed in weeks 1, 3 and 6 were within an acceptable range of -13.6% to -3.5% when compared with the nominal values (± 15%). - Duration of treatment / exposure:
- The dose formulations were administered daily according to the following schedule:
In the males:
- 2 weeks before pairing,
- during the pairing period,
- until sacrifice (at least 5 weeks in total),
In the females:
2 weeks before pairing,
during the pairing period,
during gestation,
during lactation until day 4 p.p. inclusive,
until sacrifice for female with no delivery. - Frequency of treatment:
- Once a day
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
12 mg/kg
Basis:
other: Nominal concentration
- Remarks:
- Doses / Concentrations:
30 mg/kg
Basis:
other: Nominal concentration
- Remarks:
- Doses / Concentrations:
80 mg/kg
Basis:
other: Nominal concentration
- No. of animals per sex per dose:
- 10 males and 10 females per dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
The dose-levels were selected in agreement with the Sponsor, following the results of a previous 4-week toxicity study (1989). In this study, the test item was given in oil formulations at 12, 60 or 300 mg/kg/day to Wistar rats. Severe effects, principally on the kidneys, stomach and thymus, and two deaths were reported at 300 mg/kg/day. At 60 mg/kg/day, there were similar findings in kidneys and stomach but to a lesser degree. The dose-level of 12 mg/kg/day was considered as the NOEL in the 4 week toxicity study (HOFF, 1989). - Positive control:
- Not applicable
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: once a day
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: Yes
The body weight of each male will be recorded on the first day of treatment (day 1), then once a week until sacrifice.
The body weight of each female will be recorded on the first day of treatment (day 1), then once a week until mated (or until sacrifice for females with no evidence of mating), on days 0, 7, 14 and 20 p.c. (post-coitum) and on days 1 and 5 p.p.
FOOD CONSUMPTION:
The quantity of food consumed by each male will be measured once a week, over a 7-day period, from the first day of treatment until the start of the pairing period.
The quantity of food consumed by each female will be measured once a week, over a 7-day period, from the first day of treatment until the start of the pairing period, during gestation for the intervals days 0-7, 7-14 and 14-20 p.c. and during lactation for the interval days 1-5 p.p.
During the pairing period, food consumption will not be measured for males or females.
Food intake per animal and per day will be calculated by noting the difference between the food given and that in the food-hopper the next time.
WATER CONSUMPTION: No - Sacrifice and pathology:
- SACRIFICE
On completion of the treatment period, all F0 animals were deeply anesthetized by an intraperitoneal injection of sodium pentobarbital and sacrificed by exsanguination
- Male animals: All surviving animals after the end of the pairing period (at least 5 weeks of treatment in total)
- Maternal animals: All surviving animals
+Females: on day 5 p.p.,
+Females which did not deliver on days 23 or 25 p.c.
GROSS NECROPSY
- A macroscopic post-mortem examination of the principal thoracic and abdominal organs was performed on all animals. Special attention was paid to the reproductive organs and to the internal surface of the esophagus and stomach.
HISTOPATHOLOGY / ORGAN WEIGHTS
The tissues indicated in Table 1 were prepared for microscopic examination and weighed, respectively. - Other examinations:
- Clinical signs
-The pups will be observed daily for clinical signs, abnormal behavior and external abnormalities.
Body weight
-The body weight of each pup will be recorded on days 1 and 5 p.p. - Statistics:
- See table "statistiques CIT.doc" in attached document
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- See Body weight table and food comsumption table
- Food consumption and compound intake (if feeding study):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Kidneys and thymus
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Effect on kidney, forestomach and thymus
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Details on results:
- CLINICAL SIGNS AND MORTALITY
There were no unscheduled deaths. There were no test item-related clinical signs. Incidental findings in test item-treated groups included: cutaneous lesions, areas of hair loss, and reddish vaginal discharge.
BODY WEIGHT AND WEIGHT GAIN
There were no test item-related effects on mean body weight in males. In the absence of any dose relationship, the statistically significantly higher mean body weight gain noted at 30 mg/kg/day when compared with controls was considered to be fortuitous.
There were no test item-related effects on mean body weight and mean body weight change in females during the pre-mating and gestation periods at any dose-level.
At 80 mg/kg/day, between days 1 and 5 p.p. (lactation period), half of the females lost weight (up to -8% of body weight), and the others generally had a lower body weight gain than controls. This led to statistically significantly lower mean body weight on day 5 p.p. when compared with controls. This was considered to be test item-related but non adverse.
At 12 and 30 mg/kg/day, there was a trend to a minimally dose-related lower mean body weight gain. However, in the absence of any statistical significance and effects on mean body weight on day 5 p.p., this was considered to be of no toxicologically relevance
Food consumption
There were no test item-related effects on mean food consumption in males.
There were no test item-related effects on mean food consumption in females during the pre-mating and gestation periods at any dose-level.
At 80 mg/kg/day, there was a statistically significantly lower mean food consumption from days 1 to 5 p.p. correlating with the effect seen on mean body weight. This was considered to be test item-related but non adverse.
At 30 mg/kg/day, there was a trend towards a lower mean food consumption at the same period, but in the absence of statistical significance and in view of the slight amplitude of the difference from controls, this was considered to be of no toxicologically relevance.
OPHTHALMOSCOPIC EXAMINATION
No examination performed
HAEMATOLOGY
No examination performed
CLINICAL CHEMISTRY
No examination performed
URINALYSIS
No examination performed
NEUROBEHAVIOUR
No examination performed
ORGAN WEIGHTS
The mean terminal body weight was statistically significantly lower in females given 80 mg/kg/day (p<0.05).
When compared with controls, the mean absolute and relative kidney weights were higher in females given 80 mg/kg/day, reaching a statistically significant level for the relative weight (p<0.05).
The mean absolute and relative weights of thymus were minimally lower in females given 80 mg/kg/day. This change correlated with the lymphoid atrophy seen microscopically.
The mean absolute and relative weights of testes were minimally higher in males given 80 mg/kg/day, reaching a statistically significant level for the absolute weight (p<0.05). Since no histological correlates were seen, this change was considered to be of limited toxicological importance and non adverse.
GROSS PATHOLOGY
A few treatment-related changes were seen at necropsy in kidneys, forestomach and thymus.
Kidneys
Enlargement of kidneys was seen in 2/10 females given 80 mg/kg/day. In one animal, this was associated with tan discoloration. These changes correlated histologically with tubular dilation and tubular basophilia.
Forestomach
White deposit was seen on the forestomach in 2/10 males given 80 mg/kg/day and a white mass was seen in 1/10 females. These changes correlated histologically with hyperplasia of squamous cells.
Thymus
Small thymus (reduced in size) was observed in 1/10 females given 12 mg/kg/day, 1/10 females given 30 mg/kg/day and 2/10 females given 80 mg/kg/day. This correlated histologically with lymphoid atrophy.
Red discoloration in the thymus, scabs seen on the skin and enlarged spleen were considered to be part of the normal background of changes commonly seen in the rat
HISTOPATHOLOGY: NON-NEOPLASTIC
Treatment-related changes were seen in kidneys, forestomach, stomach and thymus.
Kidneys
Kidney treatment-related changes were seen in both sexes at 80 mg/kg/day, but particularly in females and at 30 mg/kg/day in females. These included tubular necrosis, present in one high-dose group female but mainly basophilia and tubular dilation with peritubular mononuclear cell infiltrate (occasionally associated with a few fibroblasts). Mixed cell infiltrate was seen in papilla in females given 80 mg/kg/day. Granular casts and cellular debris (mix of desquamed and inflammatory cells including granulocytes) were seen in tubules.
At 12 mg/kg/day, no treatment-related changes were seen in kidneys. Tubular basophilia was seen at a slightly higher incidence than in the control group, however as this was seen unilaterally and focally, any relationship with the test item was considered to be unlikely at this dose-level.
Forestomach/stomach
Pronounced changes were observed in the forestomach at 80 mg/kg/day in both sexes and also at a lesser severity at 30 mg/kg/day.
These consisted of hyperplasia of squamous cells associated with hyperkeratosis, edema and inflammation. In one male and one female given 80 mg/kg/day, this was associated with erosion/ulcer. Spongiosis was seen particularly in males at the level of the limiting ridge.
These changes correlated with those seen at necropsy.
At 12 mg/kg/day, no test item-related changes were seen in the forestomach. In the stomach (glandular portion) the parietal cells appeared to be clear, particularly in males given 80 mg/kg/day. At 30 mg/kg/day, this was seen in 2/10 males only. No changes were noted at 12 mg/kg/day.
The exact nature of this change remained unclear but may correspond to degranulation of the parietal cells. This was not associated with any other treatment related changes (e.g erosion or ulceration of the gastric mucosa) and therefore was considered not to be adverse.
Thymus
Increased incidence of lymphoid atrophy was seen in the thymus of females given 80 mg/kg/day and correlated with the slightly decreased thymic weights. Hemorrhage was observed at a high incidence in all groups, including controls, particularly in males, but without dose-related trend. As this change is commonly seen in rats, this was considered to be fortuitous.
Bone marrow, femur
No treatment-related changes were seen in the bone marrow, particularly in the amount of adipose tissue. In addition, no decreased cellularity was seen in treated animals when compared with controls.
Genital organs
Careful examination of testes in males and of ovaries in females did not show any treatment related changes.
Slight focal tubular atrophy was seen unilaterally in testes of one male given 80 mg/kg/day (and a minimal atrophy involving a single tubule in one control male). This was associated with minimal focal Leydig cell hyperplasia. As these observations were seen unilaterally and in one animal only, these were considered to be unlikely related to the test item.
There were no histopathological changes which correlated with the slightly increased testicular weight noted at necropsy.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 12 mg/kg bw/day (nominal)
- Based on:
- act. ingr.
- Sex:
- male/female
- Basis for effect level:
- other: For parental toxicity (Treatment-related changes were seen in kidneys and forestomach at 30 and 80 mg/kg bw/day.)
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Body weight and body weight change
Mean body weights and mean body weight changes (g) are presented in the table below:
Sex |
Male |
Female |
||||||
Dose-level (mg/kg/day) |
0 |
12 |
30 |
80 |
0 |
12 |
30 |
80 |
Pre-mating (males and females) and whole study (males) |
|
|
|
|
||||
. Day 1 |
417 |
419 |
421 |
420 |
222 |
218 |
215 |
218 |
. Day 15 |
470 |
475 |
484 |
470 |
253 |
244 |
242 |
246 |
. Day 36 |
526 |
536 |
556 |
522 |
/ |
/ |
/ |
/ |
. Days 1 – 15 |
+52 |
+56 |
+63 |
+50 |
+30 |
+26 |
+27 |
+29 |
. Days 15 – 36 |
+56 |
+61 |
+72 |
+53 |
/ |
/ |
/ |
/ |
. Days 1 – 36 |
+109 |
+117 |
+135* |
+103 |
/ |
/ |
/ |
/ |
Gestation |
|
|
|
|
|
|
|
|
. Day 0p.c. |
/ |
/ |
/ |
/ |
257 |
253 |
251 |
247 |
. Day 20p.c. |
/ |
/ |
/ |
/ |
411 |
418 |
412 |
401 |
. Days 0 - 20p.c. |
/ |
/ |
/ |
/ |
+154 |
+165 |
+161 |
+154 |
Lactation |
|
|
|
|
|
|
|
|
. Day 1p.p. |
/ |
/ |
/ |
/ |
313 |
309 |
310 |
302 |
. Day 5p.p. |
/ |
/ |
/ |
/ |
326 |
320 |
317 |
297* |
Differences from controls |
/ |
/ |
/ |
/ |
/ |
-2% |
-3% |
-9% |
. Days 1 - 5p.p. |
/ |
/ |
/ |
/ |
+13 |
+11 |
+7 |
-4** |
/: not applicable;Statistically significant: *: p<0.05, **: p<0.01.
Food consumption
Sex |
Female |
|||
Dose-level (mg/kg/day) |
0 |
12 |
30 |
80 |
Lactation |
|
|
|
|
Days 1- 5p.p. |
41 |
40 |
36 |
31** |
Differences from controls |
/ |
-2% |
-12% |
-24% |
Organ weight
Sex |
Male |
Female |
||||
Group |
2 |
3 |
4 |
2 |
3 |
4 |
Dose-level (mg/kg/day) |
12 |
30 |
80 |
12 |
30 |
80 |
Exam. animals / Num. of animals |
10/10 |
10/10 |
10/10 |
9/10 |
9/10 |
10/10 |
Body weight |
+2 |
+6 |
-1 |
-1 |
-2 |
-8* |
- Kidneys |
|
|
|
|
|
|
. absolute |
-2 |
0 |
-3 |
-3 |
+1 |
+28 |
. relative |
-4 |
-5 |
-3 |
-2 |
+3 |
+40* |
- Testes |
|
|
|
|
|
|
. absolute |
+6 |
+2 |
+9* |
|
|
|
. relative |
+4 |
-3 |
+9 |
|
|
|
- Thymus |
|
|
|
|
|
|
. absolute |
+2 |
+10 |
-12 |
-11 |
-8 |
-22 |
. relative |
0 |
+5 |
-11 |
-10 |
-6 |
-16 |
Kidneys
Sex |
Males |
Females |
||||||
Group |
1 |
2 |
3 |
4 |
1 |
2 |
3 |
4 |
Dose-level (mg/kg/day) |
0 |
12 |
30 |
80 |
0 |
12 |
30 |
80 |
Number of animals |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
Tubular necrosis |
||||||||
Total (mean severity) |
- |
- |
- |
- |
- |
- |
- |
1 (1.0) |
Tubular basophilia |
||||||||
Total (mean severity) |
7 (1.0) |
4 (1.0) |
10 (1.1) |
8 (1.8) |
2 (1.5) |
5 (1.0) |
6 (1.5) |
10 (3.0) |
Tubular dilation |
||||||||
Total (mean severity) |
1 (1.0) |
2 (1.0) |
- |
3 (1.3) |
1 (1.0) |
- |
3 (1.3) |
9 (2.4) |
Infiltrate; mononuclear cells |
||||||||
Total (mean severity) |
3 (1.0) |
- |
2 (1.0) |
3 (1.0) |
- |
- |
1 (1.0) |
9 (1.1) |
Cellular debris in tubules |
||||||||
Total (mean severity) |
- |
- |
- |
1 (1.0) |
- |
- |
- |
6 (1.3) |
Cast, granular |
||||||||
Total (mean severity) |
- |
- |
- |
1 (1.0) |
- |
- |
- |
8 (1.4) |
Infiltrate, granulocytes |
||||||||
Total (mean severity) |
- |
- |
- |
- |
- |
- |
- |
6 (1.0) |
Desquamation, tubular lumen |
||||||||
Total (mean severity) |
- |
- |
- |
- |
- |
- |
2 (1.0) |
- |
Edema (tip of papilla) |
||||||||
Total (mean severity) |
- |
- |
- |
- |
- |
- |
1 (1.0) |
1 (1.0) |
-: not observed in this group.
Forestomach/stomach treatment-related changes
Sex |
Males |
Females |
||||||
Group |
1 |
2 |
3 |
4 |
1 |
2 |
3 |
4 |
Dose-level (mg/kg/day) |
0 |
12 |
30 |
80 |
0 |
12 |
30 |
80 |
Number of animals |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
Erosion/ulcer |
||||||||
Total (mean severity) |
- |
- |
- |
1 |
- |
- |
- |
1 |
Hyperplasia; squamous cell |
||||||||
Total (mean severity) |
- |
- |
5 |
8 |
- |
- |
2 |
10 |
Hyperkeratosis |
||||||||
Total (mean severity) |
- |
- |
2 |
6 |
- |
- |
- |
6 |
Edema |
||||||||
Total (mean severity) |
- |
- |
- |
3 |
- |
- |
- |
5 |
Inflammation |
||||||||
Total (mean severity) |
- |
- |
- |
4 |
- |
- |
- |
4 |
Spongiosis |
||||||||
Total (mean severity) |
- |
- |
1 |
9 |
- |
- |
- |
1 |
-: not observed in this group.
Forestomach/stomach treatment-related changes
Sex |
Males |
Females |
||||||
Group |
1 |
2 |
3 |
4 |
1 |
2 |
3 |
4 |
Dose-level (mg/kg/day) |
0 |
12 |
30 |
80 |
0 |
12 |
30 |
80 |
Number of animals |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
Erosion/ulcer |
||||||||
Total (mean severity) |
- |
- |
- |
1 |
- |
- |
- |
1 |
Hyperplasia; squamous cell |
||||||||
Total (mean severity) |
- |
- |
5 |
8 |
- |
- |
2 |
10 |
Hyperkeratosis |
||||||||
Total (mean severity) |
- |
- |
2 |
6 |
- |
- |
- |
6 |
Edema |
||||||||
Total (mean severity) |
- |
- |
- |
3 |
- |
- |
- |
5 |
Inflammation |
||||||||
Total (mean severity) |
- |
- |
- |
4 |
- |
- |
- |
4 |
Spongiosis |
||||||||
Total (mean severity) |
- |
- |
1 |
9 |
- |
- |
- |
1 |
-: not observed in this group.
Stomach
Sex |
Males |
Females |
||||||
Group |
1 |
2 |
3 |
4 |
1 |
2 |
3 |
4 |
Dose-level (mg/kg/day) |
0 |
12 |
30 |
80 |
0 |
12 |
30 |
80 |
Number of animals |
10 |
10 |
10 |
10 |
10 |
NA |
10 |
10 |
Clear parietal cells |
||||||||
Total (mean severity) |
1 |
- |
2 |
10 |
- |
|
- |
1 |
Thymus
Sex |
Males |
Females |
||||||
Group |
1 |
2 |
3 |
4 |
1 |
2 |
3 |
4 |
Dose-level (mg/kg/day) |
0 |
12 |
30 |
80 |
0 |
12 |
30 |
80 |
Number of animals |
10 |
NA |
10 |
10 |
10 |
10 |
10 |
10 |
Lymphoid atrophy |
||||||||
Minimal |
- |
|
- |
1 |
1 |
3 |
1 |
4 |
Slight |
- |
|
- |
- |
- |
- |
1 |
1 |
Moderate |
- |
|
- |
- |
- |
- |
- |
1 |
Total |
1 |
|
- |
1 |
1 |
3 |
2 |
6 |
Applicant's summary and conclusion
- Conclusions:
- Based on the experimental conditions of this study: the No Observed Adverse Effect Level (NOAEL) for parental toxicity was considered to be 12 mg/kg/day, based on the effects observed on the kidney and forestomach at 30 and 80 mg/kg bw/day.
- Executive summary:
In a screening reproductive toxicity (OECD 421, 1995), OPA (Octylphosphinic Acid) was administered to male and female Spargue-Dawley rats, 10/dose/sex, by oral gavage at the dose levels of 0, (vehicle), 12, 30, 80 mg/kg bw/day. The test substance was administered by gavage every day from 14 days prior to the start of mating, until day 5 post-partum for the females and at least for 5 weeks for the males.
Clinical signs, food consumption, body weight, Organ weights, macroscopic and histopathological examinations were performed.
There were no test item-related deaths or clinical signs in F0 animals. There were no toxicologically significant effects on mean body weight and mean food consumption in males at any dose-level or in females at 12 and 30 mg/kg/day. At 80 mg/kg/day, there were no test item related effects on mean body weight and mean food consumption during the pre-mating and gestation periods. However from days 1 and 5p.p., the females either lost weight (up to -8% of body weight) or gained less body weight than controls, leading to lower mean body weight on day 5p.p.when compared with controls (-9%, p<0.05). This correlated with low mean food consumption during that period (-24% from controls, p<0.01). These effects were considered to be test item-related but non adverse.
At necropsy, A few treatment-related changes were seen at necropsy in kidneys, forestomach and thymus.
Kidney treatment-related changes were seen in both sexes at 80 mg/kg/day, but particularly in females and at 30 mg/kg/day in females. These included tubular necrosis, present in one high-dose group female but mainly basophilia and tubular dilation with peritubular mononuclear cell infiltrate (occasionally associated with a few fibroblasts). Mixed cell infiltrate was seen in papilla in females given 80 mg/kg/day. Granular casts and cellular debris (mix of desquamed and inflammatory cells including granulocytes) were seen in tubules. At 12 mg/kg/day, no treatment-related changes were seen in kidneys. Tubular basophilia was seen at a slightly higher incidence than in the control group, however as this was seen unilaterally and focally, any relationship with the test item was considered to be unlikely at this dose-level.
Pronounced changes were observed in the forestomach at 80 mg/kg/day in both sexes and also at a lesser severity at 30 mg/kg/day. These consisted of hyperplasia of squamous cells associated with hyperkeratosis, edema and inflammation. In one male and one female given 80 mg/kg/day, this was associated with erosion/ulcer. Spongiosis was seen particularly in males at the level of the limiting ridge. These changes correlated with those seen at necropsy. At 12 mg/kg/day, no test item-related changes were seen in the forestomach.
In the stomach (glandular portion) the parietal cells appeared to be clear, particularly in males given 80 mg/kg/day. At 30 mg/kg/day, this was seen in 2/10 males only. No changes were noted at 12 mg/kg/day. The exact nature of this change remained unclear but may correspond to degranulation of the parietal cells. This was not associated with any other treatment related changes (e.g erosion or ulceration of the gastric mucosa) and therefore was considered not to be adverse.
Increased incidence of lymphoid atrophy was seen in the thymus of females given 80 mg/kg/day and correlated with the slightly decreased thymic weights. Hemorrhage was observed at a high incidence in all groups, including controls, particularly in males, but without dose-related trend. As this change is commonly seen in rats, this was considered to be fortuitous.
No treatment-related changes were seen in the bone marrow, particularly in the amount of adipose tissue. In addition, no decreased cellularity was seen in treated animals when compared with controls.
Based on the experimental conditions of this study, the NOAEL for parental toxicity was 12 mg/kg bw/day (kidney and forestomach effects at 30 and 80 mg/kg bw/day).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.